{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:05:21Z","timestamp":1792209921883,"version":"4.4.0"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":112,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive condition primarily affecting older adults, who are at increased risk of morbidity and mortality. In HELIOS-B, vutrisiran reduced all-cause mortality and recurrent cardiovascular events versus placebo in patients with ATTR-CM. This prespecified analysis evaluated efficacy and safety outcomes by age category (&amp;lt;75, 75 to &amp;lt;80, and \u226580\u2009years) and across age as a continuous measure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>HELIOS-B randomized patients with ATTR-CM in a 1:1 ratio to vutrisiran 25\u2009mg or placebo every 12\u2009weeks for up to 36\u2009months. Eligible patients were aged 18\u201385\u2009years. We assessed the primary composite of all-cause mortality and recurrent cardiovascular events, changes in 6-min walk test (6MWT) and Kansas City Cardiomyopathy Questionnaire overall summary score (KCCQ-OSS), and safety outcomes across age groups. Among 654 patients (aged 45\u201385\u2009years; mean 75.3\u2009\u00b1\u20096.7), 257 (39.3%) were &amp;lt;75, 201 (30.7%) 75 to &amp;lt;80, and 196 (30.0%) \u226580\u2009years. Vutrisiran reduced the risk of the primary composite outcome in all age categories (pinteraction\u2009=\u20090.56) and across the age spectrum as a continuous function (pinteraction\u2009=\u20090.50). Consistent benefits were seen for individual outcome components, with no significant interaction between treatment and age. Functional capacity and quality of life were preserved across age groups (pinteraction\u2009=\u20090.35 and\u2009=\u20091.00 for KCCQ-OSS and 6MWT, respectively). Safety was comparable across groups, with no increase in adverse events in older patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Vutrisiran reduced all-cause mortality and cardiovascular events and maintained function and quality of life in patients with ATTR-CM across the age spectrum, including those \u226580\u2009years.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.70084","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T11:08:48Z","timestamp":1761736128000},"page":"2971-2978","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and Safety of Vutrisiran in Transthyretin Amyloid Cardiomyopathy Across the Age Spectrum: The HELIOS-B Trial"],"prefix":"10.1093","volume":"27","author":[{"given":"Awais","family":"Sheikh","sequence":"first","affiliation":[{"name":"National Amyloidosis Centre, University College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi Michael","family":"Miao","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Claggett","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Garcia-Pavia","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBERCV, and Centro Nacional de Investigaciones Cardiovasculares (CNIC) , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cappelli","sequence":"additional","affiliation":[{"name":"Tuscan Regional Amyloid Center, Careggi University Hospital , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre","family":"Aldinc","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals , Cambridge, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Gillmore","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, University College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Fontana","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, University College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"2026021721530180900_ejhf70084-bib-0001","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: A position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"2026021721530180900_ejhf70084-bib-0002","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026021721530180900_ejhf70084-bib-0003","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jacc.2019.05.052","article-title":"Age-related characteristics and outcomes of patients with heart failure with preserved ejection fraction","volume":"74","author":"Tromp","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026021721530180900_ejhf70084-bib-0004","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1001\/jamacardio.2020.0359","article-title":"Enrollment of older patients, women, and racial\/ethnic minority groups in contemporary acute coronary syndrome clinical trials: A systematic review","volume":"5","author":"Tahhan","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2026021721530180900_ejhf70084-bib-0005","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/eurjhf\/hft028","article-title":"Heart failure in elderly patients: Distinctive features and unresolved issues","volume":"15","author":"Lazzarini","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026021721530180900_ejhf70084-bib-0006","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1002\/ejhf.2483","article-title":"Use of evidence-based therapy in heart failure with reduced ejection fraction across age strata","volume":"24","author":"Tolfo","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026021721530180900_ejhf70084-bib-0007","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.863179","article-title":"Assessment and management of older patients with transthyretin amyloidosis cardiomyopathy: Geriatric cardiology, frailty assessment and beyond","volume":"9","author":"Irabor","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2026021721530180900_ejhf70084-bib-0008","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026021721530180900_ejhf70084-bib-0009","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"2026021721530180900_ejhf70084-bib-0010","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/cpt.1974","article-title":"Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting N-acetylgalactosamine-small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects","volume":"109","author":"Habtemariam","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"2026021721530180900_ejhf70084-bib-0011","first-page":"211","article-title":"Vutrisiran in patients with transthyretin cardiac amyloidosis","volume":"390","author":"Fontana","year":"2024","journal-title":"N Engl J Med"},{"key":"2026021721530180900_ejhf70084-bib-0012","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/12\/2971\/66836722\/eurjhf_27_12_2971.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/12\/2971\/66836722\/eurjhf_27_12_2971.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T02:53:09Z","timestamp":1771383189000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/27\/12\/2971\/8470696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":12,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,10,29]]},"published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.70084","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"2025-08-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}